Cargando…

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

BACKGROUND: Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). Our study aims to assess the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yu, Wu, De-Pei, Liu, Qi-Fa, Xu, Lan-Ping, Liu, Kai-Yan, Zhang, Xiao-Hui, Yu, Wen-Jing, Xu, Yang, Huang, Fen, Huang, Xiao-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724335/ https://www.ncbi.nlm.nih.gov/pubmed/31481121 http://dx.doi.org/10.1186/s13045-019-0781-y

Ejemplares similares

Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis
por: Zhou, Xiao, et al.
Publicado: (2022)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood
por: Xu, Xiaoqian, et al.
Publicado: (2020)

Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia
por: Nagler, Arnon, et al.
Publicado: (2020)

Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation
por: Liu, Jiangying, et al.
Publicado: (2015)

Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors
por: Li, Ting, et al.
Publicado: (2022)

Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis
por: Salas, Maria Queralt, et al.
Publicado: (2019)

Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia
por: Barkhordar, Maryam, et al.
Publicado: (2022)

Anti-Thymocyte Globulin (ATG)-Free Nonmyeloablative Haploidentical PBSCT Plus Post-Transplantation Cyclophosphamide Is a Safe and Efficient Treatment Approach for Pediatric Acquired Aplastic Anemia
por: Chen, Rong-Long, et al.
Publicado: (2022)

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study
por: Li, Xingying, et al.
Publicado: (2023)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

T‐cell replete haploidentical stem cell transplantation with low dose anti‐thymocyte globulin for relapsed/refractory Ewing sarcoma family tumors
por: Sano, Hideki, et al.
Publicado: (2021)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study
por: Lin, Ren, et al.
Publicado: (2019)

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study
por: Yang, Jun, et al.
Publicado: (2018)

P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
por: Dachy, F., et al.
Publicado: (2022)

Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
por: Tang, Lu, et al.
Publicado: (2023)

High‐dose post‐transplant cyclophosphamide impairs γδ T‐cell reconstitution after haploidentical haematopoietic stem cell transplantation using low‐dose antithymocyte globulin and peripheral blood stem cell graft
por: Stocker, Nicolas, et al.
Publicado: (2020)

Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients
por: Ma, Xiaodi, et al.
Publicado: (2023)

Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models
por: Mashima, Kiyomi, et al.
Publicado: (2021)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Therapy of severe aplastic anemia with anti-human thymocyte globulin (ATGAM) with and without HLA-haploidentical bone-marrow infusion.
por: Kim, K. Y.
Publicado: (1986)

Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide
por: Toyosaki, Masako, et al.
Publicado: (2018)

Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy
por: Nawas, Mariam T., et al.
Publicado: (2023)

Modest dose anti-thymocyte globulin administered intraoperatively is safe and effective in kidney transplantations: a retrospective study
por: Liu, Hui-Ying, et al.
Publicado: (2019)

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis
por: Gao, Wen-hui, et al.
Publicado: (2023)

Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation
por: Retière, Christelle, et al.
Publicado: (2018)

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia
por: Huang, Zhenli, et al.
Publicado: (2022)

Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases
por: Even-Or, Ehud, et al.
Publicado: (2020)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

Antithymocyte Globulin Plus Post-Transplant Cyclophosphamide Combination as an Effective Strategy for Graft-versus-Host Disease Prevention in Haploidentical Peripheral Blood Stem Cell Transplantation for Children with High-Risk Malignancies
por: Wu, Kang-Hsi, et al.
Publicado: (2022)

P1293: LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH G-CSF/ATG BASED HAPLOIDENTICAL PROTOCOL PROVIDES FAVORABLE DECREASE IN ACUTE GRAFT-VERSUS-HOST DISEASE FOR SAA PATIENTS
por: Xiao-DI, MA, et al.
Publicado: (2023)

Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin
por: Zazula, Roman, et al.
Publicado: (2007)

Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation
por: Alloway, Rita R., et al.
Publicado: (2019)

Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome
por: Choi, Mihong, et al.
Publicado: (2020)

Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies
por: Gu, Zhenyang, et al.
Publicado: (2017)

Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023)

Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
por: Law, Arjun Datt, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6c6534k8368pn4gc5m00eups48